These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Trends in Otitis Media Incidence After Conjugate Pneumococcal Vaccination: A National Observational Study. Gisselsson-Solen M Pediatr Infect Dis J; 2017 Nov; 36(11):1027-1031. PubMed ID: 28657970 [TBL] [Abstract][Full Text] [Related]
13. Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine. Poehling KA; Szilagyi PG; Grijalva CG; Martin SW; LaFleur B; Mitchel E; Barth RD; Nuorti JP; Griffin MR Pediatrics; 2007 Apr; 119(4):707-15. PubMed ID: 17403841 [TBL] [Abstract][Full Text] [Related]
14. Long-term effect of pneumococcal conjugate vaccines on tympanostomy tube placements. Sarasoja I; Jokinen J; Lahdenkari M; Kilpi T; Palmu AA Pediatr Infect Dis J; 2013 May; 32(5):517-20. PubMed ID: 23190780 [TBL] [Abstract][Full Text] [Related]
15. Register-Based Ecologic Evaluation of Safety Signals Related to Pneumococcal Conjugate Vaccine in Children. Artama M; Rinta-Kokko H; Nohynek H; Jokinen J; Palmu AA Curr Drug Saf; 2018; 13(2):107-112. PubMed ID: 29623819 [TBL] [Abstract][Full Text] [Related]
16. Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997-2004. Zhou F; Shefer A; Kong Y; Nuorti JP Pediatrics; 2008 Feb; 121(2):253-60. PubMed ID: 18245415 [TBL] [Abstract][Full Text] [Related]
17. Vaccine effectiveness of the pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against clinically suspected invasive pneumococcal disease: a cluster-randomised trial. Palmu AA; Jokinen J; Nieminen H; Syrjänen R; Ruokokoski E; Puumalainen T; Moreira M; Schuerman L; Borys D; Kilpi TM Lancet Respir Med; 2014 Sep; 2(9):717-27. PubMed ID: 25127244 [TBL] [Abstract][Full Text] [Related]
18. Pneumococcal conjugate vaccination in children with recurrent acute otitis media: a therapeutic alternative? van Kempen MJ; Vermeiren JS; Vaneechoutte M; Claeys G; Veenhoven RH; Rijkers GT; Sanders EA; Dhooge IJ Int J Pediatr Otorhinolaryngol; 2006 Feb; 70(2):275-85. PubMed ID: 16140397 [TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden. Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274 [TBL] [Abstract][Full Text] [Related]
20. New vaccines against otitis media: projected benefits and cost-effectiveness. O'Brien MA; Prosser LA; Paradise JL; Ray GT; Kulldorff M; Kurs-Lasky M; Hinrichsen VL; Mehta J; Colborn DK; Lieu TA Pediatrics; 2009 Jun; 123(6):1452-63. PubMed ID: 19482754 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]